Estrogen and tibolone metabolite levels in blood and breast tissue of postmenopausal women recently diagnosed with early-stage breast cancer and treated with tibolone or placebo for 14 days

被引:5
作者
Kloosterboer, Helenius J. [1 ]
Loefgren, Lars [2 ]
von Schoulz, Eva [3 ]
von Schoultz, Bo [4 ]
Verheul, Herman A. M. [1 ]
机构
[1] NV Organon, Dept Res & Dev, NL-5340 BH Oss, Netherlands
[2] Capio St Goran Hosp, Dept Surg, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden
[4] Karolinska Univ Hosp, Dept Obstet & Gynecol, Stockholm, Sweden
关键词
tibolone metabolites; estrogen metabolites; tissue level; breast; postmenopausal;
D O I
10.1177/1933719106298679
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Unlike estrogens plus progestagens, tibolone, a selective tissue estrogenic activity regulator, does not increase breast tenderness and mammographic density. To elucidate this, serum and breast levels of tibolone and estrogenic metabolites are measured. Postmenopausal women (n = 102) with early-stage, ER+ve, primary breast cancer received tibolone or placebo for 14 days in an exploratory, double-blind, randomized trial (STEM carcinoma tissue). Baseline and presurgery sera were collected; tumor tissues were obtained at surgery. E-1 (estrone), E-2 (estradiol), E1S (estrone-sulfate), tibolone-its nonsulfated, monosulfated, and disulfated 3-hydroxymetabolites-and Delta(4)-tibolone were measured by validated gas chromatography and mass spectrometry and liquid chromatography with tandem mass spectrometry assays. More than 12 hours after the final dose, serum E-1, E-2, and E1S levels were unchanged with placebo, whereas tibolone significantly increased E1S and the E1S/(E-1 + E-2) ratio. In tumors, E-1 and E-2 levels were higher than in serum, and E1S levels were lower, with placebo and tibolone administration. The percentage of E1S was about 90% in serum and 16% in tissue. Tibolone did not affect tissue levels of endogenous estrogens. Serum levels of estrogenic 3 alpha- and 3 beta-hydroxytibolone, progestagenic/androgenic Delta(4)-tibolone, and monosulfate metabolites were low. Serum 3 alpha S, 17 beta S-tibolone and 3 beta S, 17 beta S-tibolone levels were 250 and 52 ng/mL, respectively. Tumor levels of 3 alpha- and 3 beta-hydroxytibolone and Delta(4)-tibolone were higher than in serum, but disulfate levels were lower. The percentage of sulfated tibolone metabolites was 99% in serum and 96% in tumor. Serum metabolite Patterns Of estradiol and tibolone are different from those in tissues and are compatible with neutral effects of tibolone on breast Ki67 expression.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 40 条
[21]   Tissue-selective effects of tibolone on the breast [J].
Kloosterboer, HJ .
MATURITAS, 2004, 49 (01) :S5-S15
[22]  
Kubista E., 2006, EJC Supplements, V4, P126, DOI 10.1016/S1359-6349(06)80290-9
[23]   Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density [J].
Lundström, E ;
Christow, A ;
Kersemaekers, W ;
Svane, G ;
Azavedo, E ;
Söderqvist, G ;
Mol-Arts, M ;
Barkfeldt, J ;
von Schoultz, B .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2002, 186 (04) :717-722
[24]   Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients [J].
Mady, EA ;
Ramadan, EEDH ;
Ossman, AA .
DISEASE MARKERS, 2000, 16 (3-4) :151-157
[25]   Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting [J].
Morales, L ;
Neven, P ;
Paridaens, R .
CURRENT OPINION IN ONCOLOGY, 2005, 17 (06) :559-565
[26]   Effect of tibolone on breast symptoms resulting from postmenopausal hormone replacement therapy [J].
Palomba, S ;
Di Carlo, C ;
Morelli, M ;
Russo, T ;
Noia, R ;
Nappi, C ;
Mastrantonio, P ;
Zullo, F .
MATURITAS, 2003, 45 (04) :267-273
[27]   Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer [J].
Pasqualini, JR ;
Chetrite, GS .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 93 (2-5) :221-236
[28]   Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients [J].
Pasqualini, JR ;
Chetrite, G ;
Blacker, C ;
Feinstein, MC ;
Delalonde, L ;
Talbi, M ;
Maloche, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (04) :1460-1464
[29]   Tibolone, transdermal estradiol or oral estrogen-progestin therapies: Effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels [J].
Pluchino, N ;
Genazzani, AD ;
Bernardi, F ;
Casarosa, E ;
Pieri, M ;
Palumbo, M ;
Picciarelli, G ;
Gabbanini, M ;
Luisi, M ;
Genazzani, AR .
GYNECOLOGICAL ENDOCRINOLOGY, 2005, 20 (03) :144-149
[30]   Inhibition of oestrone sulphatase activity by tibolone and its metabolites [J].
Purohit, A ;
Malini, B ;
Hooymans, C ;
Newman, SP .
HORMONE AND METABOLIC RESEARCH, 2002, 34 (01) :1-6